menu
    • menu

    Company profile for Hoth Therapeutics

    NEW Drugs in Dev: 16
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Hoth Therapeutics is a development stage biopharmaceutical company focused on proprietary therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. To treat indications impacting more than 32 million Americans, Hoth is working to develop and commercialize the BioLexa™ Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Pl...
    Hoth Therapeutics is a development stage biopharmaceutical company focused on proprietary therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. To treat indications impacting more than 32 million Americans, Hoth is working to develop and commercialize the BioLexa™ Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform has achieved positive results at preclinical studies conducted at the University of Miami.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Hoth TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Rockefeller Plaza Suite 1039 New York, New York 10020
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://hoththerapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PCHi

    PCHi

    Not Confirmed

    envelop Contact Supplier

    PCHi

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hoth Therapeutics Accelerates HT-001 Trial on Patient Demand
    Hoth Therapeutics Accelerates HT-001 Trial on Patient Demand

    24 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hoth-therapeutics-accelerates-ht-001-trial-enrollment-with-new-clinical-site-as-patient-demand-increases-302696240.html

    PR NEWSWIRE
    24 Feb 2026
    Share Share
    Hoth Gets U.S. Notice For Exon-Skipping Targeting Allergy Disease
    Hoth Gets U.S. Notice For Exon-Skipping Targeting Allergy Disease

    12 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hoth-therapeutics-receives-us-notice-of-allowance-for-novel-exon-skipping-therapy-targeting-allergic-diseases-302686267.html

    PR NEWSWIRE
    12 Feb 2026
    Share Share
    Hoth Therapeutics Reports HT-VA GDNF Outperforms Semaglutide
    Hoth Therapeutics Reports HT-VA GDNF Outperforms Semaglutide

    10 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-groundbreaking-positive-results-hoths-ht-va-gdnf-surpasses-semaglutide-in-weight-loss-glucose-control-and-liver-health-in-obesity-model-302682954.html

    PR NEWSWIRE
    10 Feb 2026
    Share Share
    Hoth Therapeutics Denies Holding Cryptocurrency Assets
    Hoth Therapeutics Denies Holding Cryptocurrency Assets

    05 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hoth-therapeutics-addresses-market-rumor-hoth-holds-no-crypto-currency-assets-302680194.html

    PR NEWSWIRE
    05 Feb 2026
    Share Share
    Hoth Strikes Back Against Skin Toxicities But Stock Stays Frozen
    Hoth Strikes Back Against Skin Toxicities But Stock Stays Frozen

    22 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/hoth-strikes-back-against-cancer-drug-skin-toxicities-share-price-stays-frozen

    FIERCE BIOTECH
    22 Jan 2026
    Share Share
    Hoth Therapeutics Secures Global Patent For HT-KIT Cancer Program
    Hoth Therapeutics Secures Global Patent For HT-KIT Cancer Program

    21 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hoth-therapeutics-secures-major-international-patent-milestone-for-ht-kit-cancer-program-strengthening-global-oncology-ip-position-302666244.html

    PR NEWSWIRE
    21 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search